Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid \r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients must not be receiving any other investigational anti-cancer agents while on study
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A/CYP3A4 agents: patients who are currently receiving drugs that are strong and moderate inducers or inhibitors of CYP3A or CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 21 days prior to enrollment to the end of the study
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed\r\n* CYP2C9 agents: patients who are currently receiving drugs that are moderate to strong inducers or inhibitor of CYP2C9 are not eligible\r\n* P-glycoprotein: patients who are currently receiving drugs that are potent inhibitors of p-glycoprotein are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or strong inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study\r\n** Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Receiving any other investigational agents or any other anti-cancer therapy
Patients currently receiving investigational or commercial anti-cancer agents or anti-cancer therapies other than BCG, ALT-803 and supportive care therapies.
Subjects who are currently receiving any other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible.
Patients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy)
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving anti-platelet agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Anti-cancer Agents\r\n* Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Prior treatment with other anti-cancer agents
Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy
Concomitant medications\r\n* Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anticonvulsants: Patients who are receiving enzyme-inducing anticonvulsants are not eligible\r\n* Anticoagulants: Use of warfarin is not allowed while on study; patients already on warfarin should use alternative anticoagulants while on this study; warfarin must not have been administered within 7 days of enrollment\r\n* Smoking: Patients must not smoke for 10 days prior to enrollment and for the duration of therapy
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: Patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
Concomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; corticosteroids must be held for 24 hours prior to initiation of study therapy\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible; the definition of “investigational” for use in this protocol means any drug that is not licensed by the Food and Drug Administration (FDA)\r\n* Anti-cancer agents: Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible (except leukemia patients who relapsed on maintenance therapy or patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy); intrathecal therapy may be given up to one week prior to initiation of study treatment\r\n* Anti-graft versus host disease (GVHD) or agents to prevent organ rejection post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial; at least 3 half-lives must have elapsed after the last dose of GVHD meds\r\n* Angiotensin-converting enzyme (ACE) inhibitors: Patients who are currently receiving ACE inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with everolimus + ACE inhibitors; at least 3 half-lives must have elapsed after the last dose of ACE inhibitors\r\n* Anti-convulsants: Patients who are currently receiving CYP3A4/PgP enzyme inducing anticonvulsants (eg. phenytoin, phenobarbitol, or carbamazepine) are not eligible; stabilizing on a non-hepatic inducing metabolizing anti-convulsant (ie: gabapentin or levetiracetam) prior to study entry is acceptable; at least 3 half-lives must have elapsed after the last dose of enzyme inducing anti-convulsants\r\n* Inhibitors of everolimus metabolism: Patients receiving treatment with azoles such as fluconazole or voriconazole which are potent inhibitors of everolimus metabolism; at least 3 half-lives must have elapsed after the last dose of azoles
Receiving any other investigational agents or any other anti-cancer therapy
Patients may not be receiving any other anti-neoplastic agents
Concomitant Medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* CYP3A4 active agents: Patients must not be receiving any of the following potent CYP3A4 inducers or inhibitors (erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John’s wort)\r\n* Patients who are receiving systemic therapeutic treatment anticoagulation are not eligible; patients receiving prophylactic systemic anticoagulation will be allowed with heparin or low-molecular-weight heparin (LMWH) as long as eligibility PT/INR requirements are met; concomitant anticoagulation with oral anticoagulations (e.g. warfarin, direct thrombin and factor Xa inhibitors) or platelet inhibitors (eg. clopidogrel) are not allowed\r\n* Enzyme-inducing anticonvulsants: Patients must not have received enzyme–inducing anticonvulsants within 14 days prior to enrollment \r\n* QTc Agents: Patients who are receiving drugs that prolong QTc are not eligible
Patients who are currently receiving other anti-cancer/devices agents are NOT eligible for either Stratum
Patients may not be receiving any other investigational and/or anti-cancer agents
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study\r\n* CYP2C19 agents: patients who are currently receiving drugs that are strong CYP2C19 inducers (e.g., rifampin, ritonavir) or inhibitors (e.g.., fluoxetine, fluvoxamine, ticlopidine) are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible.
Patient is NOT receiving any other anti-cancer agents or radiotherapy at the time of study entry
Patients must NOT receive other anti-cancer agents while on study
Patients must not be currently receiving other anti-cancer agents
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study
Patients who are currently receiving other anti-cancer agents
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving or plan to receive other anti-cancer agents (except hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy and intrathecal chemotherapy)
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study
Patients who are currently receiving other anti-cancer agents with the exception of those delineated in the eligibility criteria
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy); patients with acute lymphoblastic leukemia may receive intrathecal therapy
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents, with the exception of hydroxyurea for patients with ALCL, are not eligible
Anti-neoplastic agents
Patients who are currently receiving other anticancer agents are not eligible
Patients receiving any other investigational agents or any additional anti-cancer agents
Patients may not be receiving any other investigational agents; patients cannot be receiving concomitant chemotherapy, radiotherapy, experimental therapy or any other therapy for the purposes of anti-cancer treatment
Patients receiving other anti-neoplastic agents are excluded
Concomitant medications\r\n* Patients receiving stable or decreasing corticosteroids are not eligible for other concurrent conditions (e.g. asthma, autoimmune diseases, rash, documented adrenal insufficiency) are eligible for this study\r\n* Patients who are currently receiving another investigational drug are not eligible\r\n* Patients who are currently receiving other anti-cancer agents are not eligible
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Currently receiving other anti-cancer agents
Patients who are currently receiving other anti-cancer agents are excluded from this trial
Patients receiving any other investigational anti-cancer agents
Patients who are currently receiving other anti-cancer agents are not eligible
Receiving any other investigational agents or any other anti-cancer therapy
Patients may not be receiving any other investigational agents or active anti-neoplastic therapies
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Subjects currently receiving anti-cancer therapies (other than SSAs, which may continue).
Treatment with any anti-cancer agents within 28 days of study entry
Treatment with any anti-cancer agents within 28 days of study entry
Patients who are currently receiving other anti-cancer agents are not eligible except for hydroxyurea (which may be continued until 24 hours prior to start of protocol therapy)
All cancer patients receiving chemotherapy agents
Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from hematological and bone marrow suppression effects of prior chemotherapy.
Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects).
Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects).
Anti-cancer Agents: Patients who are currently receiving other anticancer agents are not eligible. Patients must have fully recovered from the effects of prior chemotherapy, generally at least 3 weeks from the most recent administration (6 weeks for nitrosoureas).
Patients must not currently be using other anti-cancer agent
Anti-cancer agents: must not be receiving other anti-cancer agents at time of enrollment and must not be planning to take other anti-cancer agents during DLT period